SEROLOGICAL TESTING AND TREATMENT FOR P. VIVAX: FROM A CLUSTER-RANDOMISED TRIAL IN ETHIOPIA AND MADAGASCAR TO A MOBILE-TECHNOLOGY SUPPORTED INTERVENTION

间日疟原虫的血清学检测和治疗：从埃塞俄比亚和马达加斯加的整群随机试验到移动技术支持的干预措施

• 批准号: 10039171
• 金额: $ 215.97万
• 依托单位: LONDON SCH OF HYGIENE AND TROP MEDICINE
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10039171
• 关键词: SEROLOGICAL; TESTING; TREATMENT; P.; VIVAX

Plasmodium vivax (P. vivax) is considered the most difficult human malaria to eliminate because of the inability of conventional diagnostics to detect individuals with latent liver forms. These individuals account for 80% of all infections and can readily infect mosquitoes. Currently countries can test knowing this has little impact or treat everyone which exposes individuals to drugs with potentially dangerous side effects. Parasite specific antibody responses have been shown to correlate with the likelihood of hypnozoite carriage and can be used to identify individuals who should be treated. The project aim is to implement a Cluster-Randomised Trial in Ethiopia and Madagascar to demonstrate the effectiveness of a new anti-malaria intervention based on P. vivax serological testing and treatment (PvSTATEM) with primaquine to prevent the relapse infections responsible for maintaining P. vivax transmission. Simultaneously, it will assess social and health system acceptability of such an approach as well as refine new mobile technologies which interface with point-of-care diagnostic tests and guide treatment decisions. The overarching aim to reduce malaria burden at both the individual and population level in two countries which experience the highest levels of P.vivax in Africa with the expectation of having a significant effect in reducing morbidity and improving health. It will ensure community engagement and assess the adoption of new technologies that align with those existing in the health system. The proposal is built on equal partnership and shared capacity to address a substantial public health burden.

由于常规诊断能力检测患有潜在的肝脏形式的人，因此Vivax（Vivax）被认为是消除最困难的人类疟疾。这些人占所有感染的80％，并且可以容易感染蚊子。目前，各国可以测试知道这几乎没有影响或对待每个人，这些人将个人暴露于潜在危险副作用的药物中。寄生虫特异性抗体反应已证明与催眠仪的可能性相关，可用于识别应接受治疗的个体。该项目的目的是在埃塞俄比亚和马达加斯加实施一项集群随机试验，以证明基于维瓦克斯血清学测试和治疗（PVSTATEM）的新抗马拉里亚干预的有效性（PVSTATEM）与Primaquine一起以防止复发感染负责维持Vivax P. Vivax传播。同时，它将评估这种方法的社会和卫生系统的可接受性，并完善与护理点诊断测试和指导治疗决策相互作用的新移动技术。总体旨在减轻两个国家的个人和人口水平的疟疾负担，这些国家经历了非洲阶段最高水平的水平，期望在降低发病率和改善健康方面产生重大影响。它将确保社区参与并评估与卫生系统中存在的新技术的采用。该提案建立在平等合作伙伴关系和共同能力上，以解决重大的公共卫生负担。